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Abstract 
There is increasing recognition that women have a higher prevalence of certain psychiatric 
illnesses, and a differential treatment response and course of illness compared to men. 
Additionally, clinicians deal with a number of disorders like premenstrual syndrome (PMS), 
premenstrual dysphoric disorder (PMDD) and postpartum depression, which affect women 
specifically and for which treatment and biological pathways are still unclear. In this article 
we highlight recent research which suggests that different biological mechanisms may 
underlie sex differences in responsiveness to stress.  Sex differences are evident at the 
receptor level; where corticotropin releasing factor receptor (CRF1) shows differential 
coupling to adaptor proteins in males and females. The neuropeptide oxytocin also shows 
sex-specific effects in a range of social behaviours. It may act as a biomarker in post-
traumatic stress disorder (PTSD) where sex differences are evident. Studies in women using 
hormonal contraception show that some of these oxytocin mediated effects are likely 
influenced by sex hormones. In female rats rapid changes in circulating progesterone levels 
are associated with exaggerated behavioural responses to mild stress and blunted response 
to benzodiazepines that could be prevented by acute treatment with low dose fluoxetine. 
Perceived barriers in research on women have hindered progress. The development of a sex 
specific psychopharmacology as a basis for translating this type of research into clinical 
practice is vital to improve treatment outcomes for women.  
Word count-223  
Keywords: sex differences, sex hormones, gender, oestrogen, estrogen, progesterone, 
neurosteroids, allopregnanolone, oxytocin. 
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Introduction 
The World Health Organization recognizes sex as a crucial factor determining the prevalence 
and severity of mental health problems (World Health Organization, 2000). Some disorders 
affect women exclusively: approximately 20% of women of reproductive age experience 
premenstrual syndrome (PMS) and 3-8% of women experience premenstrual dysphoric 
disorder (PMDD) (Halbreich et al., 2003, Halbreich et al., 2007). Women are twice as likely to 
suffer from depression and anxiety disorders and have higher rates of attempted suicide 
(Mergl et al., 2015) while men have a higher risk of substance use disorders, some 
neurodevelopmental conditions and death by suicide (Eaton et al., 2012; McCarthy and 
Wright, 2017); (Bekker and van Mens-Verhulst, 2007; McCarthy, 2016; W.H.O, 2015). Social, 
cultural and economic inequalities across sexes have been found to account for some of 
these disparities (World Health Organization, 2000; Kuehner, 2017). For example, women 
are more frequently the primary victims of domestic violence, which is a risk factor for 
depression (World Health Organization, 2000). The fact that a proportion of these 
differences can be explained by sociocultural factors has somehow concealed the 
importance of biological determinants (Li and Graham, 2017).  
An extensive body of literature from animal and human studies has appeared in the last 
twenty-five years describing biochemical sex differences in response to stress (McEwen and 
Milner, 2017; Carey et al., 1995; Ferrini et al., 1997). Given that stress is implicated in 
numerous psychiatric diseases including affective disorders, post-traumatic stress disorder 
and substance abuse, sex differences in stress response systems (McEwen, 2017) may 
underlie the different prevalence by sex seen in these disorders (Luine et al., 2017). Two 
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important stress response systems in which sex differences have been reported are the 
corticotropin-releasing factor (CRF) system and the brain norepinephrine system arising 
from the locus coeruleus (LC).  Additionally, differential effects between the sexes have 
been found in the effectiveness, side effect profile and pharmacokinetics of psychotropic 
drugs (Bigos et al., 2009; Marazziti et al., 2013). As an example, zolpidem, one of the most 
widely prescribed drugs for insomnia is known to have lower clearance in women and the 
FDA recommends different doses for men and women (Greenblatt et al., 2014; FDA, 2014). 
However, despite growing evidence suggesting differential pharmacological effects, the 
underlying mechanisms remain woefully under-researched. In this review, we aim to 
highlight some specific aspects of the current research in the literature in this area, focusing 
specifically on sex differences in stress response systems such as corticotropin-releasing 
factor and the brain norepinephrine systems, female neurophysiology and the contribution 
of sex hormones, allopregnanolone and oxytocin to sex differences in stress-responsiveness 
and psychiatric illness. The authors contributed to a symposium on this topic held at the 
British Association for Psychopharmacology Summer Meeting 2016. 
Stress-responsiveness and corticotropin releasing factor signalling 
Life stressors have been implicated in many of the major psychiatric disorders that are more 
prevalent in females compared to males, including depression and post-traumatic stress 
disorder (PTSD)(Choi et al., 2016; van der Meer et al., 2016; Olff et al., 2007). Individuals 
with these disorders often exhibit features of a dysfunctional hypothalamic-pituitary-
adrenal (HPA) axis (Arnett et al., 2016). As a result, most investigations into sex differences 
in neuropsychiatric disease have focused on stress hormones or the HPA axis. Psychiatric 
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diseases that are more prevalent in females also share symptoms of hyperarousal, 
characterized by sleep disturbances, restlessness, and inability to concentrate.   
The major brain norepinephrine (NE) system that arises from the pontine nucleus locus 
coeruleus (LC) is a stress responsive structure that regulates arousal and cognitive responses 
to stress through a network of widely distributed projections to the cortex (Aston-Jones and 
Cohen, 2005; Valentino and Van Bockstaele, 2008; Valentino et al., 2013a). This system is 
activated in parallel with the HPA axis by many of the same triggers and its stimulation is 
associated with increased arousal, and cognitive flexibility. This LC response to stress is 
mediated by corticotropin-releasing factor (CRF), the same neuropeptide released by the 
HPA axis to initiate the endocrine limb of the stress response. The combined neurohormone 
and neurotransmitter function of CRF may coordinate endocrine and cognitive responses to 
life-threatening challenges. Although LC-NE activation would be adaptive in response to an 
acute stressor, inappropriate or persistent activation of this system could produce the 
pathological hyperarousal that characterizes stress-related psychiatric disorders. 
In unstressed rats, the basic neuronal characteristics of LC neurons, such as spontaneous 
discharge rate and sensory-evoked discharge, are comparable between males and females 
(Curtis et al., 2006). However, LC neurons of female rats are sensitized to CRF and this is 
manifested as a greater activation by certain stressors (Curtis et al., 2006). Receptor 
immunoprecipitation studies revealed a molecular basis for this in the differential coupling 
of the CRF receptor (CRF1) to adaptor proteins in males and females (Bangasser et al., 2010). 
For example, in unstressed rats, we found that CRF1 showed greater association with its 
GTP-binding protein Gs, in females compared to males, consistent with a greater CRF-
elicited neuronal activation. Like other G-protein coupled receptors, CRF1 internalizes 
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following agonist binding and is transported into multivesicular bodies, a step towards CRF1 
downregulation (Reyes et al., 2006; Reyes et al., 2008). CRF1 internalization is initiated by its 
association with β-arrestin-2. This process protects neurons from excessive CRF. In an 
experiment with rats exposed to swim stress, both increased CRF1 coupling to β-arrestin-2 
and CRF1 internalization were found in males compared to females (Bangasser et al., 2010). 
The greater coupling of CRF1 to Gs and the impaired ability of β-arrestin-2 to associate with 
CRF1 is predicted to render LC neurons of females more sensitive to stress and less able to 
adapt by receptor internalization. In the absence of stress, sex differences in CRF receptor 
signalling would have no consequences because there is no tonic influence of CRF. However, 
sex differences in LC activity will be apparent and magnified in conditions in which CRF 
release is excessive as has been proposed in stress-related psychiatric disorders such as 
depression and post-traumatic stress disorder. This condition can be modelled in mice that 
are genetically modified to overexpress CRF (CRF-OE mice). Both male and female CRF-OE 
mice show hyperinnervation of the LC by CRF axon terminals and there is no sex difference 
in this innervation (Bangasser et al., 2012). Based on this, LC neuronal discharge rates are 
predicted to be higher in both male and female CRF-OE mice compared to wildtype animals. 
Recordings from LC slices of male and female wildtype revealed no sex difference in LC 
discharge rates. Surprisingly, LC neuronal discharge rates of male CRF-OE mice were similar 
to wildtype mice indicating that they were protected from CRF overexpression (Bangasser et 
al., 2012). In contrast, LC discharge rates of female CRF-OE mice were nearly three times 
greater than all other groups.  Electron microscopic analysis suggested that this was due to a 
lack of CRF1 internalization in females (Bangasser et al., 2012). Whereas CRF1 was 
predominantly localized to the cytoplasm in male CRF-OE mice, in female CRF-OE mice it 
appeared mainly in the plasma membrane leaving the cells vulnerable to excessive CRF in 
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the synapse. This combination of increased sensitivity due to enhanced CRF1-Gs binding and 
decreased ability to internalize CRF1 as a result of decreased CRF1-β-arrestin-2 association 
could make females more vulnerable to stress-related disorders.  
Because Gs and β-arrestin-2 engage different cellular signalling pathways, the sex bias in 
CRF1 coupling predicts that stress will initiate sex-specific cellular reactions in males and 
females (Valentino et al., 2013b). These can translate to sex specific physiological and 
behavioural responses to stress and sex-specific stress-related pathology. These sex 
differences would be magnified under conditions of elevated CRF release, which are 
believed to occur in certain stress-related psychiatric disorders that show a female 
prevalence, including depression and PTSD (Banki et al., 1987; Bremner et al., 1997; 
Nemeroff et al., 1984).  Supporting this, male and female CRF-OE mice have distinct cortical 
phosphoproteomic profiles that can be accounted for in part by sex biases in CRF1 coupling 
to Gs and -arrestin-2 (Bangasser et al., 2016).  Distinctions between these profiles may 
reveal substrates that are the basis for sex differences in the prevalence of stress-related 
diseases.             
In addition to differences at the postsynaptic level, sex differences in afferents that mediate 
the response of the LC-norepinephrine system to stress could account for sex biases in 
stress-related diseases.  Some of the circuitry underlying LC activation by different stimuli 
has been delineated (Van Bockstaele et al., 2001).  For example, LC activation by 
hypotensive stress and social stress is mediated by CRF amygdalar afferents, while LC 
activation by colonic distention is mediated in part by Barrington’s nucleus (Curtis et al., 
2002; Reyes et al., 2015; Rouzade-Dominguez et al., 2001).  The possibility that there are sex 
differences in CRF expression or release from these afferents requires future investigation. 
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Impact of sex hormones and allopregnanolone in PMS and PMDD. 
During the luteal phase of the menstrual cycle, many women develop adverse psychological 
and physical symptoms collectively known as premenstrual syndrome (PMS). The most 
commonly reported psychological symptoms included anger and irritability, mood swings, 
tearfulness, fatigue, lack of energy, and food cravings (Ryu and Kim, 2015). Premenstrual 
Dysphoric Disorder (PMDD) is commonly characterized as a severe type of PMS. The current 
DSM-5 diagnosis requires a perimenstrual pattern of physical, behavioural and/or mood 
related symptoms with special emphasis on the severity of psychological symptoms 
(American Psychiatric Association, 2013). Typically, symptoms peak during the late luteal 
phase and resolve shortly after the onset of menstruation (Halbreich et al, 2003). The 
cyclical change in secretion of progesterone during the menstrual cycle may be one of the 
factors that contribute to the development of these negative mood states in susceptible 
women. Following ovulation progesterone secretion increases markedly, remains elevated 
during the luteal phase, before returning to basal levels immediately prior to menstruation 
(Fig 1-A). However, there is considerable individual variation in hormone levels and women 
who developed symptoms of PMS displayed a significantly different luteal phase salivary 
progesterone profile compared to women who remained asymptomatic (Lovick et al., 2017). 
Whereas early luteal phase progesterone concentration was similar in both groups, in 
women who remained asymptomatic progesterone showed a gradual linear decline 
throughout the mid and late luteal phase right up to the onset of menstruation (Fig 1-B). In 
contrast, in women who developed symptoms of PMS, progesterone remained at a 
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relatively high and stable level during the early and mid-luteal phase before undergoing a 
sharp decline during the three days prior to menstruation (Fig 1-C) (Lovick et al., 2017).  
Progesterone, as well as its neuroactive steroid metabolite allopregnanolone, passes readily 
through the blood brain barrier and in the brain its concentration parallels that in the 
plasma (Pardridge et al., 1980). Progesterone, via the action of allopregnanolone, exerts 
dose-related anxiogenic and anxiolytic effects in women, characterised by an inverted U-
shaped dose-response relationship (Andréen et al., 2009). Interestingly, in post-menopausal 
women in whom endogenous progesterone concentration remains at a stable low level, 
daily administration of progesterone at doses sufficient to achieve a physiological 
concentration was associated with a progressive worsening of negative mood (Andréen et 
al., 2006). This response mimics the progressive worsening in severity of symptoms that 
occurs in PMS sufferers who display a stable elevated level of progesterone during the early 
to mid-luteal phase (Lovick et al., 2017). The mechanism that underlies the effect of 
prolonged exposure to progesterone is not completely understood but may be linked to 
tolerance effects [see (Turkmen et al., 2011) for a review of this topic]. 
Paradoxically, in women who developed PMS, symptoms worsened even further during the 
sharp decline progesterone concentration in the 3 days prior to menstruation (Lovick et a, 
2017). In animal models, withdrawal from progesterone following prolonged exposure 
precipitated anxiogenic effects (Devall et al., 2009) (Smith et al., 1998). However, such 
effects were seen only when the withdrawal was rapid and were absent if the steroid 
concentration was allowed to fall gradually (Doornbos et al., 2009), in line with the absence 
of PMS symptoms in women in whom progesterone underwent a slow linear decline during 
the whole luteal phase (Lovick et al, 2017). It is well established in rats that a rapid decline in 
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progesterone, either following cessation of prolonged dosing, or during the natural decline 
that occurs during the late diestrus phase, can precipitate changes in GABAA receptor 
expression associated with an increase in behavioural measures of anxiety-like behaviour 
and an increase in excitability of neural circuits controlling fear and anxiety (Smith et al., 
1998; Brack and Lovick, 2007; Devall et al., 2009; Devall et al., 2015). The effect is mediated 
not by progesterone itself but via the decline in its neuroactive metabolite 
allopregnanolone. Interestingly, in spontaneously cycling rats the anxiogenic effects 
precipitated by an abrupt decline in progesterone could be prevented by offsetting the 
rapid fall in brain concentration by short-term treatment in the late diestrus phase with the 
SSRI fluoxetine (Devall et al, 2015). At low doses, fluoxetine increases brain 
allopregnanolone concentration without affecting 5-hydroxytryptamine systems, a property 
which is shared by other SSRIs (Pinna et al, 2009;Devall et al, 2009).  By raising the brain 
concentration of allopregnanolone, administration of fluoxetine during late diestrus would 
offset the rapid fall in concentration of the steroid that normally occurs at this time. In this 
context, it is interesting that when allopregnanolone but not progesterone levels, were 
stabilized during the late luteal phase in women with PMDD by blocking the conversion of 
progesterone to allopregnanolone, luteal phase symptoms of irritability, anxiety and 
sadness reduced significantly (Martinez et al., 2016). 
Clinically, selective serotonin reuptake inhibitors (SSRIs) are offered for the management of 
premenstrual syndrome. The latest Cochrane review (Majoribanks et al, 2013) rated the 
available evidence of only low to moderate quality but nevertheless concluded that SSRIs 
are effective in reducing the symptoms of PMS although adverse effects were relatively 
frequent. Interestingly, treatment was equally effective whether taken continuously or only 
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during the two weeks prior to menstruation (the luteal phase).  This finding raises questions 
regarding the mechanisms of action of SSRIs for PMS.  Their effectiveness as antidepressants 
typically requires a long lead in time to produce therapeutic effects via actions on 5-HT 
systems. Yet therapeutic effects for PMS can be obtained by short term dosing during the 
luteal phase (Majoribanks et al, 2013). In animal studies acute administration of SSRIs at 
doses subthreshold for effects on 5-HT systems has been shown to produce a rapid 
elevation in brain allopregnanolone (Pinna et al, 2009 Devall et al, 2015). Moreover, short-
term dosing with low dose of the SSRI fluoxetine, was effective in reducing late diestrus 
phase anxiety (a model for PMS) (Devall et al, 2015).  These findings suggest not only that 
the doses currently used in clinical practice, which are based on those developed for 
antidepressant actions, may be far higher than necessary but also that the effectiveness of 
SSRIs for PMS may be linked to their steroid stimulating properties, rather than uptake of 
serotonin.  
Whilst a change in progesterone secretion during the menstrual cycle can clearly have a 
significant influence on brain function and behaviour in females, it may also a factor, 
together with actions and interactions with other gonadal hormones, that influences drug 
effects. There is evidence that progesterone-induced change in GABAA receptor status 
during the estrous cycle may influence the effectiveness of psychoactive drugs that act on 
this receptor site. For example, anxiolytic effects of a benzodiazepine seen in the early 
stages of the estrous cycle in female rats were not evoked when the drug was given in the 
late diestrus phase (Soares-Rachetti et al., 2016). In a similar vein, women who suffer with 
premenstrual syndrome (but not asymptomatic women) showed reduced sensitivity to 
benzodiazepines during the luteal phase of the menstrual cycle (Bell et al., 2004; Sundstrom 
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et al., 1997). These findings highlight the importance of taking into account female 
hormonal status when working towards developing a sex- specific pharmacology. 
Estrogen and PTSD.  
Posttraumatic Stress Disorder (PTSD) is a syndrome that can appear after exposure to a life 
threatening event, death, serious injury or violence. Symptoms include intrusive thoughts, 
nightmares, flashbacks about the traumatic event, emotional distress or physical reactivity 
after exposure to triggers related to the trauma, hypervigilance and heightened startle 
reaction (American Psychiatric Association, 2013). Patients often report experiencing 
feelings of reliving the traumatic event (Shearing et al., 2011; Hagenaars et al., 2009; 
Halligan et al., 2006). These memories trigger feelings of fear similar to those suffered 
during the event itself.   This Impaired fear extinction or the inability to extinguish a 
conditioned fear response, is a hallmark of the condition (Zuj et al., 2017; Garfinkel et al., 
2014; Fani et al., 2012). Gonadal steroids such as estrogen have been found to modulate the 
expression of fear extinction (Glover et al., 2015). Specifically, extinction deficits observed in 
women with PTSD correlate with low estrogen plasma levels (Glover et al., 2012) and the 
administration of synthetic estrogen to healthy women increased extinction recall after fear 
extinction (Graham and Milad, 2013). Moreover, both in healthy women and women with 
PTSD lower estrogen levels have been linked to impaired fear inhibition, evident in a lack of 
discrimination between danger and safety cues in a fear-potentiated startle paradigm 
(Glover et al., 2013). Estrogen levels had no effect on contingency awareness but seem to 
influence activity in an inhibitory neurocircuit. In female rats, estrogen enhances infralimbic 
control over the central amygdala during extinction recall (Maeng et al., 2017) and women 
with high estrogen levels exhibit increased dorsal lateral prefrontal cortex reactivity during 
13 
 
emotional response inhibition (Amin et al., 2006). Importantly, PTSD is also characterized by 
diminished fear inhibition and there is converging evidence from imaging studies that 
patients with PTSD show hyperreactivity of the amygdala coupled with reduced top-down 
control by the prefrontal cortex in response to trauma- and fear-associated stimuli (Etkin 
and Wager, 2007; Jovanovic and Norrholm, 2011). Recently, it has also been suggested that 
estrogen status may increase risk for PTSD in some women, in part through its epigenetic 
regulation of the HDAC4 gene, which encodes histone deacetylase 4 and is involved in long-
term memory formation (Maddox et al., 2017). The apparently contradictory findings of 
estrogen as a protective factor versus higher PTSD prevalence rates in women, who 
generally have higher estrogen levels than men, underscore the necessity to consider a 
possible interplay between multiple hormonal systems (Zuj et al., 2016).  
Role of oxytocin 
The hypothalamic neuropeptide oxytocin (OXT) has often been implicated in modulating 
fear and stress responses (Meyer-Lindenberg et al., 2011). For example, male police officers 
with PTSD show lower basal salivary OXT levels than healthy trauma-exposed controls, while 
there is no difference in females between PTSD patients and controls (Frijling et al., 2015). 
By contrast, serum OXT levels in survivors of motor vehicle accidents positively predict 
posttraumatic coping at a 1-month follow-up in women (Nishi et al., 2015). Importantly, the 
intranasal administration of synthetic OXT increases OXT concentrations in the brain 
(Striepens et al., 2013) and may thus be used as a pharmacological means to alter central 
OXT signalling. Two studies showed that OXT administered intranasally before fear 
extinction enhanced both extinction (Eckstein et al., 2015) and the recall of extinction in 
healthy men (Acheson et al., 2013). This anxiolytic effect of OXT could be mediated by a 
14 
 
down-regulation of amygdala response and a concomitant up-regulation of activity in 
prefrontal regions (Eckstein et al., 2015). However, there is mounting evidence that social 
effects of exogenous OXT are dependent upon both context and person variables 
(Hurlemann and Scheele, 2016). First and foremost, intranasal OXT may also increase fear 
conditioning when the peptide is administered before the conditioning phase (Eckstein et 
al., 2016). As such, a greater risk of developing PTSD after an interpersonal trauma may be 
associated with an OXT-induced enhancement of fear learning.  Another instance of 
context-dependency is the observation that OXT improves the buffering effect of social 
support on stress responsiveness (Heinrichs et al., 2003), but also facilitates the sensation of 
psychosocial stress in the absence of social support (Eckstein et al., 2014).  
Sex also appears to be a key moderator of OXT effects. Sex-specific OXT effects have been 
found in various domains ranging from social approach/avoidance behaviour (Scheele et al., 
2012; Preckel et al., 2014) and social perception (Fischer-Shofty et al., 2013) to moral 
decision-making (Scheele et al., 2014). Some of these sex differences could be due to 
hormonal fluctuations during the menstrual cycle or the use of hormonal contraception. 
Along these lines, a recent report showed that intranasal OXT increased a positive 
attractiveness bias in the perception of the romantic partner and enhanced reward-
associated brain activations in men and freely cycling women, but not in women using 
hormonal contraception (Scheele et al., 2013; Scheele et al., 2016). Moreover, OXT 
increased amygdala responses to fearful faces (Domes et al., 2010) and aversive scenes 
(Lischke et al., 2012) in healthy women. On the flipside, OXT reduced amygdala responses to 
infant crying in healthy women (Riem et al., 2011), and higher doses of OXT dampened 
amygdala responses to fearful faces in both male and female patients with PTSD (Koch et al., 
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2016). Notably, the amygdala is not a homogenous structure but rather consists of various 
nuclei and consequently imaging with high spatial resolution may be necessary to 
disentangle differential OXT effects on amygdala substructures. For instance, it has been 
observed that OXT attenuates activation in lateral and dorsal regions of the left anterior 
amygdala for fearful faces but enhances activity in a more ventral cluster for happy 
expressions (Gamer et al., 2010). In female mice, estrogen pre-treatment enhances 
anxiolytic OXT actions (McCarthy et al., 1996), indicating that anti-anxiety effects of OXT 
may be dependent upon interactions with steroids. Given the above mentioned evidence 
for facilitating effects of estradiol on fear extinction, future human studies are warranted to 
explore possible interactions between gonadal steroids and OXT in fear learning.   
  
Perceived barriers to the development of sex based psychopharmacology research 
 
Pre-clinical research in psychopharmacology is still based predominantly on male animal 
models of disease (Kokras and Dalla, 2014). The assumption, which is probably unfounded 
(Prendergast et al., 2014), of increased variability of data obtained in females compared to 
males has historically deterred researchers from conducting experiments on females. 
Moreover where researchers have used females, there are frequent contradictions in the 
literature because the effects of the estrous cycle have not been carefully determined to 
assess whether behaviours are in fact regulated in this way or not. In many cases, the 
behavioural tasks employed have not been validated for use with female animals which may 
also contribute to the variability in behavioural outcomes (Becker and Koob, 2016). 
Differences in the expression of symptoms between males and females extend to biological 
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markers and these are not always acknowledged in research (Kokras and Dalla, 2017). While 
there is a need to include more female animals in psychopharmacology research to improve 
translational outcomes (Leger and Neill, 2016), these studies must be designed carefully to 
account for these differences.  In 2014 the National Institute of Health (NIH) introduced 
policies that required applicants to balance the use of male and female cells and animals in 
preclinical studies, unless sex-specific inclusion was unwarranted (Clayton and Collins, 
2014). This move is potentially very powerful and appears to be stimulating research into 
both women’s health issues and sex differences in disease. In the UK, the research councils 
have not issued the same mandate as NIH. However, there is increasing emphasis on the 
justification of the use of animals in research and appropriate experimental design. For 
example, the National Center for the Replacement, Refinement and Reduction of Animal 
Research (NC3Rs) experimental design hub suggests the use of an adequately powered 
factorial experimental design such that the effect of a drug can be tested on both males and 
females in the same experiment (NC3Rs). Where there is evidence of a sex difference, then 
it is necessary to assess the effects of gonadal steroids on that behaviour or drug treatment 
(Becker et al., 2005). Initially this can be achieved by establishing the effects of the estrous 
cycle. In rodents the estrous cycle is typically 4 days-a 2 day diestrous (rats) or 
metoestrus/diestrous (mice),  pro-estrous (associated with luteinizing hormone surge), and 
estrous (sexual receptivity, ovulation) (Becker et al., 2005). Changes in cell type morphology 
can be assessed in vaginal smears and used to identify the estrous phase in a relatively 
straightforward way (McLean et al., 2012; Becker et al., 2005). As one can see, there are few 
barriers to using female animals in research, and a number of potential benefits for 
translational psychopharmacology research.   
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Sex differences in clinical research 
In terms of clinical research, women have only been included in clinical trials relatively 
recently (FDA, 1993). A 2016 review of fifty-seven randomized controlled trials (RCTs) 
published in peer reviewed journals found that only 39% recruited women and men in equal 
numbers and a meagre 20% described results by sex or examined possible sex interactions 
(Phillips and Hamberg, 2016). It is even more difficult to explain greater recruitment of men 
for illnesses that have the same rates of prevalence in both sexes or higher prevalence in 
women (Phillips and Hamberg, 2016; Holdcroft, 2007). Concerns about pregnancy and 
experimenting with women of childbearing age, while possibly justifiable (Vargesson, 2015; 
Balon and Riba, 2016), led to a protectionist position and the consequence was that 
women’s health research was excluded (Mastroianni et al., 1994). Issues around ensuring 
the use of contraception to avoid potential fetal harm appear to complicate enrolment of 
women (Holdcroft, 2007). A study of contraceptive requirements for clinical research found 
that almost 42% of protocols did not explain why contraception was mandatory (Cain et al., 
2000). There is also the possibility of interaction of between medication and hormonal 
contraception. In the US 28% of women of fertility age are using some type of hormonal 
contraception (Jones et al., 2012). Excluding women from trials may hide these effects 
leading to a knowledge gap about these interactions when the drug is commercialized, 
which could potentially lead to further harm for women.  
Evidence suggests a series of social, legal, medical and perhaps institutional barriers to 
implementing equal recruitment in RCTs. Results of trials with biased recruitment may not 
apply to both sexes, but it will only be evident when the medication or intervention is 
released to the general public. A further concern is that researchers perceive that 
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investigating women’s physiology is more complicated because of lack of data and, 
specifically, the lack of replication studies (Holdcroft, 2007). This paradox can only be 
resolved by increasing research in the area and by encouraging scientists and institutions to 
prioritize sex-equal samples and the reporting of results by sex.  
Sex differences in clinical practice 
In psychiatric practice, sex differences are acknowledged in several areas such as domestic 
violence, sexual related side-effects, and perinatal mental health.  Conscious sex-differential 
prescribing based on evidence is rare as is clinical recognition of variation of drug efficacy 
across sexes even when pharmacokinetic or pharmacodynamic differences are known 
(Legato, 2004). Recent guidelines have addressed sex differences by considering guidance 
for the perinatal period (NICE, 2014) but general evidence from translational research that 
does not refer to pregnancy or breastfeeding has yet to reach the clinician.  Certain 
awareness in practice will be required to implement these changes. In some cases 
treatment protocols separated by sex may help (Mendrek and Stip, 2011). The development 
of a branch of psychopharmacology focused on sex differences will aid to structure the 
evidence and increase knowledge translation between preclinical researchers and clinical 
professionals until these findings are fully integrated in everyday medical practice.   
Word count: 4564 
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Fig 1.A. Schematic representation of time course of change in systemic and brain 
progesterone concentration during the menstrual cycle. M: menses start. B. Time course of 
mean PMS score and saliva progesterone concentration in 22 symptomatic women over the 
10 days prior to menstruation. ** p<0.01; *** p<0.001 compared to Day -10, Friedman test 
across all days followed by Dunn’s multiple comparisons. C. Time course of mean PMS score 
and saliva progesterone concentration in 12 asymptomatic women over the last 10 days 
prior to menstruation. Reproduced from Lovick et al (Lovick et al., 2017) with permission. 
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